A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Partic… (NCT06682793) | Clinical Trial Compass
RecruitingPhase 1/2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
United States240 participantsStarted 2025-05-22
Plain-language summary
The goal of this study is to test A2B395, an allogeneic logic-gated Tmodâ„¢ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression.
The main questions this study aims to answer are:
* Phase 1: What is the recommended dose of A2B395 that is safe for patients
* Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells
Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:
* Enrollment in BASECAMP-1 (NCT04981119)
* Preconditioning lymphodepletion (PCLD) regimen
* A2B395 Tmod CAR T cells at the assigned dose
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\*02 by NGS (whenever possible from the primary site).
✓. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, HNSCC, TNBC, RCC, or other solid tumors with EGFR expression. Measurable disease is required with lesions of ≥1.0 cm by CT.
✓. Received previous required therapy for the appropriate solid tumor disease as described in the protocol
✓. Has adequate organ function as described in the protocol
✓. ECOG performance status of 0 to 1
✓. Life expectancy of ≥3 months
✓. Willing to comply with study schedule of assessments including long-term safety follow-up
Exclusion criteria
✕. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative
✕
What they're measuring
1
Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level
Timeframe: From the time of Informed consent until 24 months (2 years) post A2B395 infusion
2
Phase 1: Recommended phase 2 dose (RP2D)
Timeframe: 28 days post A2B395 infusion
3
Phase 2: The overall response rate (ORR) for patients
✕. Cancer therapy within 3 weeks or 3 half lives of A2B395 infusion
✕. Radiotherapy within 28 days of A2B395 infusion
✕. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months
✕. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated
✕. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year